Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹211 Cr
Revenue (TTM)
₹118 Cr
Net Profit (TTM)
₹15 Cr
ROE
23 %
ROCE
21.1 %
P/E Ratio
14.2
P/B Ratio
2.4
Industry P/E
14.21
EV/EBITDA
12.8
Div. Yield
0.2 %
Debt to Equity
0.2
Book Value
₹44.7
EPS
₹7.4
Face value
10
Shares outstanding
20,052,000
CFO
₹-7.18 Cr
EBITDA
₹63.06 Cr
Net Profit
₹48.55 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Indo Us Bio-Tech
| -14.3 | -28.8 | -15.5 | -33.8 | -- | -- | -- |
|
BSE FMCG
| -14.1 | -8.4 | -13.8 | -8.7 | 2.4 | 6.6 | 8.6 |
|
Company
|
2025
|
|---|---|
|
Indo Us Bio-Tech
| -59.4 |
|
BSE Small Cap
| -6.6 |
|
BSE FMCG
| -2.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Indo Us Bio-Tech
|
104.2 | 210.9 | 117.8 | 14.8 | 14.6 | 18 | 14.2 | 2.4 |
| 233.0 | 1,156.1 | 1,378.9 | 101.1 | 9.9 | 13.5 | 11.4 | 1.6 | |
| 154.3 | 3,204.5 | 1,463.4 | 73.6 | 6.1 | 16.3 | 43.6 | 6.1 | |
| 255.0 | 313.9 | 493.3 | 4.4 | 0.5 | 2.7 | 75.8 | 1.9 | |
| 814.0 | 4,185.9 | 1,377.9 | 300.8 | 20.1 | 18.3 | 13.9 | 2.3 | |
| 378.5 | 13,160.9 | 10,267.2 | 636.9 | 9.0 | 16.2 | 20.2 | 3.0 | |
| 3.9 | 420.3 | 1,440.2 | 343.1 | 24.1 | 32.2 | 1.2 | 0.3 | |
| 139.8 | 266.2 | 445.5 | 43.1 | 9.9 | 5.9 | 6.2 | 0.4 | |
| 379.8 | 421.6 | 14.1 | 1.1 | 7.5 | 18.1 | 398.5 | 61.1 | |
| 3.2 | 393.2 | 1,312.7 | 33.1 | 5.1 | 8.6 | 11.9 | 0.8 |
No Review & Analysis are available.
Manufacture of food products
Incorporated
2004
Chairman
--
Managing Director
Jagdish Ajudia
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Indo US Bio-Tech Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
Announcements
View AnnouncementsClarification sought from Indo Us Bio-Tech Ltd
10-Mar-2026Results- Financial Results For December 31 2025
21-Jan-2026The share price of Indo US Bio-Tech Ltd is ₹104.19 (NSE) and ₹105.15 (BSE) as of 20-Mar-2026 IST. Indo US Bio-Tech Ltd has given a return of -33.85% in the last 1 years.
The P/E ratio of Indo US Bio-Tech Ltd is 14.21 times as on 20-Mar-2026, a 0 premium to its peers’ median range of 14.21 times.
The P/B ratio of Indo US Bio-Tech Ltd is 2.35 times as on 20-Mar-2026, a 27 premium to its peers’ median range of 1.85 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.15
|
3.76
|
|
2024
|
53.94
|
7.09
|
|
2023
|
14.71
|
3.91
|
|
2022
|
12.22
|
1.61
|
|
2021
|
3.36
|
0.93
|
The 52-week high and low of Indo US Bio-Tech Ltd are Rs 206.00 and Rs 96.05 as of 21-Mar-2026.
Indo US Bio-Tech Ltd has a market capitalisation of ₹ 211 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Indo US Bio-Tech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.